Subsidiary completes acquisition of A1 Biochem Group's contract research business

Apitoria Pharma, a wholly owned subsidiary, has completed the acquisition of the Contract Research Services business of A1 Biochem Group, after the conditions in the definitive agreements were met.

Fri 2 Oct 2026

Apitoria stake in A1 Biochem Labs (India)

80% ownership

Former promoter stake in A1 Labs India

Dr. Rajendra Gadikota, former promoter of A1 Biochem Group, holds 20%

Stake acquired in A1 Biochem Labs LLC, USA

100% membership interest

CRO platform client base

50+ client base

CRO platform projects completed

800+ completed projects

What was announced

• Apitoria Pharma Private Limited, a wholly owned subsidiary of the company, has completed the acquisition of the Contract Research Services business of A1 Biochem Group.
• The company states that the completion followed satisfaction of the conditions prescribed under the definitive agreements. This follows its earlier letters updating that Apitoria was acquiring this business.

Ownership structure after completion

• Apitoria now holds 80% ownership in A1 Biochem Labs (India) Private Limited, referred to as A1 Labs India.
• The remaining 20% ownership is held by Dr. Rajendra Gadikota, former promoter of A1 Biochem Group.
• A1 Labs India, through its wholly owned subsidiary A1 Biochem USA Inc, USA, has acquired 100% membership interest of A1 Biochem Labs LLC, USA, which is a step-down subsidiary of A1 Labs India and operates in the USA.

What the acquired platform brings

• An existing CRO (contract research organisation) platform with a 50+ client base.
• Experience of completing 800+ projects in India and USA.

What the company says it means

• The acquisition complements Apitoria's manufacturing capabilities to create an integrated CRDMO platform.
• It is intended to expand the portfolio of offerings to customers and enable longer life cycle engagement with customers.

How a retail investor can read this

• The update is an update that a previously informed acquisition has been completed, and it sets out the ownership structure that now exists.
• The acquired business is held through A1 Labs India, in which Apitoria holds a majority 80% stake, with the former promoter of A1 Biochem Group holding a minority 20% stake.
• The company describes the acquired CRO platform by its scale, a 50+ client base and 800+ completed projects.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.